Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line - PubMed (original) (raw)
. 2002 Oct 11;277(41):38884-94.
doi: 10.1074/jbc.M205518200. Epub 2002 Jul 26.
Affiliations
- PMID: 12145295
- DOI: 10.1074/jbc.M205518200
Free article
Effect of mutant alpha-synuclein on dopamine homeostasis in a new human mesencephalic cell line
Julie Lotharius et al. J Biol Chem. 2002.
Free article
Abstract
Mutations in alpha-synuclein have been linked to rare, autosomal dominant forms of Parkinson's disease. Despite its ubiquitous expression, mutant alpha-synuclein primarily leads to the loss of dopamine-producing neurons in the substantia nigra. alpha-Synuclein is a presynaptic nerve terminal protein of unknown function, although several studies suggest it is important for synaptic plasticity and maintenance. The present study utilized a new human mesencephalic cell line, MESC2.10, to study the effect of A53T mutant alpha-synuclein on dopamine homeostasis. In addition to expressing markers of mature dopamine neurons, differentiated MESC2.10 cells are electrically active, produce dopamine, and express wild-type human alpha-synuclein. Lentivirus-induced overexpression of A53T mutant alpha-synuclein in differentiated MESC2.10 cells resulted in down-regulation of the vesicular dopamine transporter (VMAT2), decreased potassium-induced and increased amphetamine-induced dopamine release, enhanced cytoplasmic dopamine immunofluorescence, and increased intracellular levels of superoxide. These results suggest that mutant alpha-synuclein leads to an impairment in vesicular dopamine storage and consequent accumulation of dopamine in the cytosol, a pathogenic mechanism that underlies the toxicity of the psychostimulant amphetamine and the parkinsonian neurotoxin 1-methyl-4-phenylpyridinium. Interestingly, cells expressing A53T mutant alpha-synuclein were resistant to amphetamine-induced toxicity. Because extravesicular, cytoplasmic dopamine can be easily oxidized into reactive oxygen species and other toxic metabolites, mutations in alpha-synuclein might lead to Parkinson's disease by triggering protracted, low grade dopamine toxicity resulting in terminal degeneration and ultimately cell death.
Similar articles
- Overexpression of human alpha-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells.
Zhou W, Hurlbert MS, Schaack J, Prasad KN, Freed CR. Zhou W, et al. Brain Res. 2000 Jun 2;866(1-2):33-43. doi: 10.1016/s0006-8993(00)02215-0. Brain Res. 2000. PMID: 10825478 - Overexpression of human alpha-synuclein causes dopamine neuron death in primary human mesencephalic culture.
Zhou W, Schaack J, Zawada WM, Freed CR. Zhou W, et al. Brain Res. 2002 Feb 1;926(1-2):42-50. doi: 10.1016/s0006-8993(01)03292-9. Brain Res. 2002. PMID: 11814405 - Impaired dopamine storage resulting from alpha-synuclein mutations may contribute to the pathogenesis of Parkinson's disease.
Lotharius J, Brundin P. Lotharius J, et al. Hum Mol Genet. 2002 Oct 1;11(20):2395-407. doi: 10.1093/hmg/11.20.2395. Hum Mol Genet. 2002. PMID: 12351575 Review. - Modulation of dopamine transporter function by alpha-synuclein is altered by impairment of cell adhesion and by induction of oxidative stress.
Wersinger C, Prou D, Vernier P, Sidhu A. Wersinger C, et al. FASEB J. 2003 Nov;17(14):2151-3. doi: 10.1096/fj.03-0152fje. Epub 2003 Sep 4. FASEB J. 2003. PMID: 12958153 - Could a loss of alpha-synuclein function put dopaminergic neurons at risk?
Perez RG, Hastings TG. Perez RG, et al. J Neurochem. 2004 Jun;89(6):1318-24. doi: 10.1111/j.1471-4159.2004.02423.x. J Neurochem. 2004. PMID: 15189334 Review.
Cited by
- Fibroblast growth factor-21 enhances mitochondrial functions and increases the activity of PGC-1α in human dopaminergic neurons via Sirtuin-1.
Mäkelä J, Tselykh TV, Maiorana F, Eriksson O, Do HT, Mudò G, Korhonen LT, Belluardo N, Lindholm D. Mäkelä J, et al. Springerplus. 2014 Jan 2;3:2. doi: 10.1186/2193-1801-3-2. eCollection 2014. Springerplus. 2014. PMID: 25932355 Free PMC article. - Interaction between Neuromelanin and Alpha-Synuclein in Parkinson's Disease.
Xu S, Chan P. Xu S, et al. Biomolecules. 2015 Jun 5;5(2):1122-42. doi: 10.3390/biom5021122. Biomolecules. 2015. PMID: 26057626 Free PMC article. Review. - Oxidative Stress in Parkinson's Disease: Potential Benefits of Antioxidant Supplementation.
Percário S, da Silva Barbosa A, Varela ELP, Gomes ARQ, Ferreira MES, de Nazaré Araújo Moreira T, Dolabela MF. Percário S, et al. Oxid Med Cell Longev. 2020 Oct 12;2020:2360872. doi: 10.1155/2020/2360872. eCollection 2020. Oxid Med Cell Longev. 2020. PMID: 33101584 Free PMC article. Review. - Recent advances and applications of human brain models.
Nishimura K, Osaki H, Tezuka K, Nakashima D, Numata S, Masamizu Y. Nishimura K, et al. Front Neural Circuits. 2024 Aug 5;18:1453958. doi: 10.3389/fncir.2024.1453958. eCollection 2024. Front Neural Circuits. 2024. PMID: 39161368 Free PMC article. Review. - Mutations in PRKN and SNCA Genes Important for the Progress of Parkinson's Disease.
Oczkowska A, Kozubski W, Lianeri M, Dorszewska J. Oczkowska A, et al. Curr Genomics. 2013 Dec;14(8):502-17. doi: 10.2174/1389202914666131210205839. Curr Genomics. 2013. PMID: 24532983 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous